First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorAzim, H. A.
dc.contributor.authorEl Saghir, N. S.
dc.contributor.authorYap, Y. S.
dc.contributor.authorEralp, Y.
dc.contributor.authorIm, S\\-A.
dc.contributor.authorSandhu, M. S.
dc.contributor.authorAbdel\\-Razeq, H.
dc.contributor.authorGupta, S.
dc.contributor.authorArtamonova, E.
dc.contributor.authorRihani, J.
dc.contributor.authorAlfaro, T. Delgar
dc.contributor.authorWu, J.
dc.contributor.authorHu, H.
dc.contributor.authorGao, M.
dc.contributor.authorLu, Y\\-S.
dc.date.accessioned2025-10-16T15:14:24Z
dc.date.issued2023
dc.description.abstractCongress of the European-Society-for-Medical-Oncology (ESMO), Madrid, SPAIN, OCT 20-24, 2023
dc.identifier.doi10.1016/j.annonc.2023.09.579
dc.identifier.otherWOS:001087480200391
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6158
dc.publisherELSEVIER
dc.sourceANNALS OF ONCOLOGY
dc.titleFirst-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS